BRK-B vs LAZ
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The deterministic health profile is weak, highlighted by a Piotroski F-Score of 3/9, indicating deteriorating operational efficiency and profitability trends. While the company maintains a fortress balance sheet with a Debt/Equity ratio of 0.19 and a Current Ratio of 7.07, the stock is trading at a significant premium to its growth-based intrinsic value of $217.21. Negative YoY revenue and earnings growth, coupled with a bearish technical trend, offset the positive analyst sentiment and long-term historical performance.
LAZ exhibits a stable but mediocre Piotroski F-Score of 4/9, while trading at a massive premium to its Graham Number ($21.31) and Intrinsic Value ($15.19). Despite strong ROE and consistent earnings beats, the company is facing a severe YoY earnings collapse of -43.30% and an unsustainable dividend payout ratio of 92.17%. Bearish insider activity and a 0/100 technical trend further signal a lack of confidence in the current price level of $48.51.
Compare Another Pair
Related Comparisons
BRK-B vs LAZ: Head-to-Head Comparison
This page compares Berkshire Hathaway Inc. (BRK-B) and Lazard, Inc. (LAZ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.